Researchers: Rosa Spinelli, Ritesh Kumar Baboota, Silvia Gogg, Francesco Beguinot, Matthias Blüher, Annika Nerstedt, Ulf Smith
Cell senescence (CS) is at the nexus between aging and associated chronic disorders, and aging increases the burden of CS in all major metabolic tissues. However, CS is also increased in adult obesity, type 2 diabetes (T2D), and nonalcoholic fatty liver disease independent of aging. Senescent tissues are characterized by dysfunctional cells and increased inflammation, and both progenitor cells and mature, fully differentiated and nonproliferating cells are afflicted. Recent studies have shown that hyperinsulinemia and associated insulin resistance (IR) promote CS in both human adipose and liver cells. Similarly, increased CS promotes cellular IR, showing their interdependence. Furthermore, the increased adipose CS in T2D is independent of age, BMI, and degree of hyperinsulinemia, suggesting premature aging. These results suggest that senomorphic/senolytic therapy may become important for treating these common metabolic disorders.
References
- Targeting Cellular Senescence for Age-Related Diseases: Path to Clinical Translation.
- Skeletal muscle aging, cellular senescence, and senotherapeutics: Current knowledge and future directions.
- Cellular senescence and senolytics: the path to the clinic.
- Targeting cellular senescence in metabolic disease.
- Molecular basis of ageing in chronic metabolic diseases.
- Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging.
- The metabolic roots of senescence: mechanisms and opportunities for intervention.
Topic: Senolytics